Less tolerance for SAEs in changing HCV landscape
(NASDAQ:VRTX) hepatitis C virus (HCV) drug VX-135 and the recent
partial clinical hold placed on it signal heightened FDA scrutiny toward
HCV drugs, experts said.
Still, most experts expressed optimism the partial hold will be removed and that the 200mg dose will advance.